Picture This: Revealing Trends for a More Robust Diagnostic Imaging Industry
Decision Resources, Inc, March 2010, Pages: 32
What will it take to make diagnostic imaging a more robust industry sector? On the one hand, imaging technology - a standard technique in diagnosing and managing cancers and neurological and cardiovascular diseases - faces resistance, deriving mainly from concerns over cost and safety, that prevents it from reaching its full potential. On the other hand, imaging technology has a growing role in clinical drug development and other therapy areas, and—even more importantly—innovative solutions to the current challenges facing this technology are being developed and are beginning to reach the marketplace. These endeavors have the potential to lift industry growth from incremental to impressive.
Questions Answered in this Report:
- Diagnostic imaging comprises six major modalities: magnetic resonance imaging (MRI), X-ray imaging, ultrasound, computed tomography (CT), single-photon emission computed tomography (SPECT), and positron emission tomography (PET). What was the value of each of these modalities in 2009, and what are their growth prospects through 2013?
- MRI is the most widely used imaging modality in industry-sponsored clinical trials, especially in evaluating oncology indications. What makes MRI the leader in this category? What other imaging modalities are associated with particular therapy areas?
- Information technology developments offer innovative solutions to complement diagnostic imaging modalities, such as iPhone “apps,” filmless imaging, integrated workflow systems that store and retrieve results, visualization software, and more. What is the most important barrier these innovations could face in implementation? How can novel developments in imaging offset some of the challenges?
- The diagnostic imaging industry must address a host of market-disrupting issues if it is to convert its anticipated modest growth into robust growth. How is this industry coping with constraints such as strict reimbursement rules? Will advancing technology offer viable solutions to overcome the expected barriers?
- Innovation is key. How do new approaches such as oncoimaging and colonography play a role? Can the emerging focus on electronic health records provide a boost to the diagnostic imaging industry? Will GE Healthcare’s new GE Healthymagination Fund reap benefits for the company in particular and the industry in general?
Scope:
- Imaging modalities: X-ray imaging, ultrasound, CT, MRI, PET, and SPECT.
- Therapy areas: Main coverage in oncology, cardiovascular disease, and central nervous system diseases.
- Analysis of clinical trials: Based on a review of nearly 1,800 imaging clinical trials, with a focus on over 200 industry-sponsored, ongoing studies.
- Review of dealmaking activity: Listing of select deals involving biomarker imaging January 2005- 2010; analysis of prominent dealmaking trends.
- Insight from Millennium Research Group’s diagnostic imaging market forecasts: Market value figures for 2013 for major diagnostic imaging modalities and compound annual growth rates (CAGR) during 2009-2013.
- Market constraints: Imaging facility and hospital budget restrictions, high level of regulatory scrutiny of imaging agents, strict reimbursement rules, and inadequate cost benefit analyses to demonstrate value for imaging market.
- Opportunities for industry growth: New technologies featuring improved diagnostic capabilities, enhanced software development and advancing information technology, clinical research on the safety of imaging agents, cross-collaboration between diagnostic imaging and pharmaceutical companies, and innovative solutions, such as picture archiving and communication systems (PACS), to integrate imaging data archiving with healthcare practices.
Key Terms for this Report:
Imaging, Positron emission tomography (PET), Single-photon emission computed tomography (SPECT), Magnetic resonance imaging (MRI), Computed tomography (CT), Diagnostic imaging, Picture archiving and communication systems (PACS), Software development, Contrast agent, Imaging agent, eFilm, Computer-aided detection/diagnosis (CAD), Colonography, Clinical trials, Oncoimaging
Executive Summary
Strategic Considerations
Stakeholder Implications
Overview
Key Growth Opportunities and Barriers
Select Diagnostic Imaging Technologies
X-Ray Imaging
Ultrasound
Computed Tomography
Magnetic Resonance Imaging
Nuclear Medicine Imaging: PET and SPECT Technologies
Diagnostic Imaging in Clinical Trials
Therapeutic Area Highlights
Oncology
Cardiovascular Disease
Central Nervous System
Exposure to Imaging Agents and Radiation
Advances in Information Technology
PACS Is Here
Future of PACS
Company Activity
GE Healthcare Leads the Pack
Support from Pharmaceutical Companies
Outlook
Tables
1. Select Challenges and Opportunities for Market Growth in Diagnostic Imaging
2. Main Advantages and Disadvantages of Diagnostic Imaging Modalities
Appendix A. Select Dealmaking Activity in Diagnostic Imaging, January 2005-January 2010
Figures
1. Global Diagnostic Imaging Market, 2009-2013
2. Ongoing Industry-Sponsored Clinical Trials, with Computed Tomography, by Therapeutic Area, February 2010
3. Ongoing Industry-Sponsored Clinical Trials, with Magnetic Resonance Imaging, by Therapeutic Area, February 2010
4. Ongoing Industry-Sponsored Clinical Trials, with Nuclear Medicine Imaging, by Therapeutic Area, February 2010
5. Ongoing Industry-Sponsored Clinical Trials, by Modality, February 2010
6. Ongoing Industry-Sponsored Imaging Clinical Trials, by Modality and Phase in Development, February 2010
7. Ongoing Industry-Sponsored Clinical Trials, by Therapeutic Area, February 2010
8. Leading Competitors in the Diagnostic Imaging Market, by Modality, 2008
- AC Immune
- Acusphere
- Advanced Proteome Therapeutics
- Affi body
- Affi med Therapeutics
- AG Mednet
- Agfa Healthcare
- Agilent Technologies
- Alerion Biomedical
- Alethia Biotherapeutics
- Alsace BioValley
- Anka Systems
- Aposense
- ART
- AstraZeneca
- Atreus Pharmaceuticals
- Avid Radiopharmaceuticals
- Avista Capital
- Bayer Schering Pharma
- Bexion
- BG Medicine
- BioClinica
- BioLume
- BioNanomatrix
- Biophan Technologies
- Biotage
- BioTex
- Boston Imaging Core Lab
- Boston Scientifi c
- Bracco Diagnostics
- Breakaway Imaging
- Bristol-Myers Squibb Medical Imaging
- Calgary Scientifi c
- Caliper Life Sciences
- Cancer Research Technology
- Celera
- ChemImage
- Chondrometrics
- Covidien
- Eli Lilly
- Emageon
- Escalon Medical
- Ethicon Endo-Surgery
- FluoroPharma
- Fujifi lm Medical Systems
- FutureChem
- Gamma Medica-Ideas
- GE Healthcare
- GlaxoSmithKline
- Hitachi
- Horizon Discovery
- IBA
- i3 Statprobe
- iCAD
- Ion Beam Applications
- Isogenica
- Lantheus Medical Imaging
- LEAP Technologies
- Life Technologies
- Luminetx Mammography Reporting System
- McKesson
- MDS
- Medicsight
- Medtronic
- Merck
- Meridian Technique
- MetaSystems
- Microvision
- Midatech Andalucia
- Molecular Devices
- Molecular Imaging
- Molecular Insight Pharmaceuticals
- Molecular Probes
- Molecular Targeting Technologies
- mtm laboratories
- Myriad Genetics
- Naviscan PET Systems
- NeoProbe
- NeuroPhysics
- NeuroSurvival Technologies
- Next Breath
- NovaDAQ Technologies
- Novartis
- NuView Radiopharmaceuticals
- Organon
- PeerVue
- Philips Healthcare
- PhotoCure ASA
- Pieris
- Pfi zer
- Prolume
- Protein Discovery
- ProteoTech
- ReliaGene Technologies
- Sentinelle Medical
- Siemens Healthcare
- Sigma-Aldrich
- Somanetics
- Taisho Pharmaceutical
- Terarecon
- Thinking Systems
- Translational Genomics Research Institute
- VisEn Medical
- Vital Images
- Xsira Pharmaceuticals
- Zymera
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
